Ongoing trials are investigating ICI-based combination therapies, including NCT05347212 with nivolumab plus relatlimab (LAG3 antibody) in RMC and NCT05286801 with tiragolumab (TIGIT antibody) plus atezolizumab in SMARCB1- or SMARCA4-deficient RCC [44,45]. Here, SMARCA4 is linked to renal cell adenocarcinoma.